Scarica l'app Stockscreener
0.706
3.29%
-0.024
Dopo l'orario di chiusura:
.71
0.004
+0.57%
Precedente Chiudi:
$0.73
Aprire:
$0.73
Volume 24 ore:
28,790
Relative Volume:
0.61
Capitalizzazione di mercato:
$20.26M
Reddito:
$1.13M
Utile/perdita netta:
$-20.74M
Rapporto P/E:
-0.3755
EPS:
-1.88
Flusso di cassa netto:
$-18.37M
1 W Prestazione:
-5.87%
1M Prestazione:
-4.75%
6M Prestazione:
-53.25%
1 anno Prestazione:
-30.10%
Intervallo 1D:
$0.7012
$0.74
Intervallo di 1 settimana:
$0.7012
$0.767
Portata 52W:
$0.5946
$2.115
Cyclo Therapeutics Inc Stock (CYTH) Company Profile
Nome
Cyclo Therapeutics Inc
Settore
Telefono
386-418-8060
Indirizzo
6714 NW 16TH STREET, SUITE B, GAINESVILLE
Cyclo Therapeutics Inc Borsa (CYTH) Ultime notizie
Kuehn Law Encourages CDE, SMC, COFS, and RFL Investors to Contac - GuruFocus.com
Rare Disease Spotlight: Niemann-Pick pipeline behind two approvals - BioCentury
Sonoma Pharmaceuticals (SNOA) Surges Amid Positive Analyst Ratin - GuruFocus.com
What Q3 investment banking trends reveal about the economy - Fortune
Will Cyclo Therapeutics Get A Boost From NPC-1 Trial Data? - RTTNews
Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer - citybiz
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - The Manila Times
Niemann Pick Disease Drug Type C Treatment Market Industry - openPR
Deal Watch: Lilly Turns To Oblique For Antibody Discovery - Scrip
Alkermes (ALKS) Stock Surges Amid Strong Financial Results - GuruFocus.com
Maxim Group Downgrades Cyclo Therapeutics (CYTH) - MSN
Cyclo Therapeutics faces Nasdaq delisting over non-compliance - Investing.com
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Increased by Handelsbanken Fonder AB - Defense World
Cyclo Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com UK
Cyclo Therapeutics secures $3 million in funding from Rafael Holdings By Investing.com - Investing.com South Africa
Cyclo Therapeutics secures $3 million in funding from Rafael Holdings - Investing.com India
Kuehn Law Encourages CDE, SMC, COFS, and RFL Investors to Contact Law Firm - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, SMC, COFS, RFL on Behalf of Shareholders - GlobeNewswire
SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers of RFL, PORT and MNTX - AccessWire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FYBR, COFS, RFL on Behalf of Shareholders - Lelezard.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders - AccessWire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMAR, MNTX, RFL on Behalf of Shareholders - The Malaysian Reserve
Kuehn Law Encourages RVNC, RFL, BTTR, and ARC Investors to Contact Law Firm - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, GATO, RFL on Behalf of Shareholders - The Malaysian Reserve
Take your (Niemann-) Pick: Intrabio’s Aqneursa wins FDA nod - BioWorld Online
Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World
Cyclo-oxygenase 2 Inhibitors Clinical Trial Pipeline - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COFS, ARC, NBY, RFL on Behalf of Shareholders - GlobeNewswire
Kuehn Law Encourages COFS, ARC, RFL, and NBY Investors to Contact Law Firm - The Malaysian Reserve
HC Wainwright & Co. Initiates Coverage of Cyclo Therapeutics (CYTH) with Buy Recommendation - MSN
Niemann-Pick Disease Type C Npc Market 2024 Opportunity, - openPR
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHEB, ARC, RFL on Behalf of Shareholders - The Malaysian Reserve
2024 remains record-breaker for deal value, M&A values double - BioWorld Online
Cyclo Therapeutics secures $3 million convertible note financing By Investing.com - Investing.com Australia
Biotech Working on 'Functional Cure' for Type 1 Diabetes - Streetwise Reports
Cyclo Therapeutics secures $3 million convertible note financing - Investing.com
CYTH stock touches 52-week low at $0.68 amid market challenges - Investing.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ARCH, CYTH, VGR on Behalf of Shareholders - The Malaysian Reserve
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (NasdaqCFB), Arch Resources, Inc. (NYSEARCH), Cyclo Therapeutics, Inc. (NasdaqCYTH), Vector Group Ltd. (NYSE - GlobeNewswire Inc.
Cyclo Therapeutics reports progress in NPC treatment trials - Investing.com India
Cyclo Therapeutics Presents Encouraging Preliminary Safety Data from Ongoing Pivotal Phase 3 Study and Substudy for the Treatment of Niemann-Pick Disease Type C1 (NPC1) - StockTitan
Cyclo Therapeutics Inc (CYTH) deserves deeper analysis - US Post News
What is Cyclo Therapeutics Inc (CYTH) Stock Return on Shareholders’ Capital? - SETE News
CYTH stock touches 52-week low at $0.77 amid market challenges - Investing.com
Cyclo Therapeutics Inc Azioni (CYTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.88%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):